About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Ganymede Bio raises $12.75M for data platform

Positive Dupixent eosinophilic esophagitis phase 3 results

Japanese companies look to reduce environmental impact

Spanish foodtech grows in 2022

Watch: Biocant Park – a biotech hub in the heart of Portugal

More News! 21 Dec 2022

Watch: Aphaia Pharma interview

ADVERTISEMENT

Watch: Araris Biotech at Bio-Europe

Watch: Mauritius – clinical trials and emerging biotech hub

Biomica raises $20M to advance microbiome-based therapeutics pipeline

Poolbeg identifies new potential drug candidates for RSV infections 

Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine

Anocca secures €25M to develop next-generation T-cell therapies for cancer

ADVERTISEMENT